Summit Therapeutics Inc
NASDAQ:SMMT

Watchlist Manager
Summit Therapeutics Inc Logo
Summit Therapeutics Inc
NASDAQ:SMMT
Watchlist
Price: 17.01 USD -1.28%
Market Cap: 12.7B USD

SMMT's latest stock split occurred on Sep 21, 2020

The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.

Before the split, SMMT traded at 3.38 per share. Afterward, the share price was about 3.44.

The adjusted shares began trading on Sep 21, 2020. This was the only stock split in SMMT's history.

Last Splits:
Sep 21, 2020
1-for-1
Pre-Split Price
3.38 3.38
Post-Split Price
3.44
Before
After
Last Splits:
Sep 21, 2020
1-for-1

Summit Therapeutics Inc
Stock Splits History

SMMT Stock Splits Timeline
Sep 21, 2020
Sep 21, 2020
Split 1-for-1
/1
Pre-Split Price
3.38 3.38
Post-Split Price
3.44
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.74 45.74 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60.0727 60.0727 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
50 50 USD N/A
Load More

Summit Therapeutics Inc
Glance View

Summit Therapeutics Inc., headquartered in Cambridge, Massachusetts, has carved a niche in the biopharmaceutical landscape with its focus on addressing serious unmet medical needs, primarily through the development of innovative antibiotics and therapies. The company gained significant attention with its efforts to combat antibiotic resistance, a global health threat. Their flagship endeavor, Ridinilazole, is an antibiotic designed to treat C. difficile infections, a prevalent and often severe bacterial infection affecting the gut. The company's proposition is simple yet impactful: develop effective treatments that not only address infections but also potentially reduce recurrence, thereby offering a better therapeutic alternative to existing solutions. Summit's business model is built around advancing their drug pipeline through rigorous clinical trials, securing regulatory approvals, and ultimately achieving commercialization either independently or through strategic partnerships. The partnerships are critical, as they allow Summit to leverage the expertise and market reach of larger pharmaceutical companies. Additionally, these alliances provide financial backing, helping offset the costly nature of drug development. Revenue is primarily driven from these collaborations through milestone payments and eventual product royalties, once their therapies hit the market. This strategic approach allows Summit to focus its resources on research and development while aligning with partners to navigate the complexities of bringing new therapies to patients globally.

SMMT Intrinsic Value
Not Available
Back to Top